Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A4 | P26447 | 7/20 | 0.49 |
| ▸ | CDC25B | P30305 | 3/20 | 0.49 |
| ▸ | TDP2 | O95551 | 3/20 | 0.47 |
| ▸ | NSD2 | O96028 | 3/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 3/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | PTPRC | P08575 | 2/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.43 |
| ▸ | PADI1 | Q9ULC6 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27616642 | 0.77 | TDP2 (0.46) | S100A4CDC25BTDP2NSD2PAX8 | |
| SCHEMBL28754189 | 0.73 | MAPT (0.44) | S100A4CDC25BTDP2NSD2PAX8 | |
| SCHEMBL16047148 | 0.72 | IDO1 (0.41) | S100A4CDC25BTDP2PLCG1CES1 | |
| SCHEMBL29727870 | 0.72 | IDO1 (0.41) | S100A4CDC25BTDP2PLCG1CES1 | |
| SCHEMBL30665385 | 0.71 | TDP2 (0.56) | S100A4CDC25BTDP2NSD2PAX8 | |
| SCHEMBL2604368 | 0.71 | TDP2 (0.56) | S100A4CDC25BTDP2NSD2PAX8 | |
| SCHEMBL829095 | 0.68 | TDP2 (0.52) | S100A4CDC25BTDP2NSD2PAX8 | |
| SCHEMBL22990892 | 0.67 | TDP2 (0.50) | S100A4CDC25BTDP2NSD2PAX8 | |
| Hydrochloric Acid SCHEMBL11105978 | 0.67 | TDP2 (0.50) | S100A4CDC25BTDP2NSD2PAX8 | |
| SCHEMBL28057220 | 0.67 | S100A4 (0.47) | S100A4CDC25BTDP2NSD2PAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951939-B2 | Multivalent platform molecules comprising high molecular weight polyethylene oxide | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2005-10-04 | — | — | US | claimed |
| US-20050175620-A1 | Multivalent platform molecules comprising high molecular weight polyethylene oxide | LA JOLLA PHARMACEUTICAL CO. | 2005-08-11 | — | — | US | disclosed |
| EP-1292337-A2 | MULTIVALENT PLATFORM MOLECULES COMPRISING HIGH MOLECULAR WEIGHT POLYETHYLENE OXIDE | LA JOLLA PHARMACEUTICAL (US) | 2003-03-19 | — | — | EP | disclosed |
| US-20020110535-A1 | Multivalent platform molecules comprising high molecular weight polyethylene oxide | LA JOLLA PHARMACEUTICAL COMPANY | 2002-08-15 | — | — | US | disclosed |
| US-20020107389-A1 | Conjugates of chemically defined non-polymeric valency platform molecules and biologically active molecules | LA JOLLA PHARMACEUTICAL COMPANY | 2002-08-08 | — | — | US | disclosed |
| US-20020082400-A1 | Conjugates of T cell epitope deficient immunogen analogs for humoral anergy and chemically defined non-polymeric valency platform molecules | LA JOLLA PHARMACEUTICAL COMPANY | 2002-06-27 | — | — | US | disclosed |
| WO-2001093914-A2 | MULTIVALENT PLATFORM MOLECULES COMPRISING HIGH MOLECULAR WEIGHT POLYETHYLENE OXIDE | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050175620-A1 | Multivalent platform molecules comprising high molecular weight polyethylene oxide | TLR3, ACP1, TLR9 | S100A4 2116/4885CDC25B 4024/4885TDP2 2586/4885 |
| US-20020110535-A1 | Multivalent platform molecules comprising high molecular weight polyethylene oxide | TLR3, ACP1, TLR9 | S100A4 2116/4885CDC25B 4024/4885TDP2 2586/4885 |
| US-20020082400-A1 | Conjugates of T cell epitope deficient immunogen analogs for humoral anergy and chemically defined non-polymeric valency platform molecules | SSB, CD4, LY96 | S100A4 2555/4885CDC25B 923/4885TDP2 316/4885 |
| US-20020107389-A1 | Conjugates of chemically defined non-polymeric valency platform molecules and biologically active molecules | SSB, PCNA, NASP | S100A4 1532/4885CDC25B 2797/4885TDP2 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.